Bend Bioscience

Bend Bioscience is a private, revenue-generating CDMO focused on solving complex drug delivery challenges for small molecule therapeutics. The company has recently expanded its cGMP facilities in Oregon, adding four new suites to bolster its commercial spray drying and particle engineering capabilities. It positions itself as a full-service partner from concept to commercial supply, serving biopharma clients with a domestic U.S. operational base. Recent news includes a development agreement with Starton Therapeutics for an oral controlled-release formulation of lenalidomide.

Integrated CDMO platform specializing in spray drying, particle engineering, and formulation design for oral bioavailability enhancement and complex dosage forms (multiparticulates, modified release) for small molecules.

Bend Bioscience competes in the specialized CDMO space focused on complex oral dosage forms and solubility enhancement. Key competitors include global CDMOs with advanced drug product capabilities (e.g., Catalent, Lonza, Recipharm) and niche U.S.-based players specializing in spray drying and particle engineering (e.g., Ascendia Pharma, Pharmatek, now part of Catalent). Its differentiation lies in its integrated service model, domestic U.S. commercial-scale spray drying, and a stated focus on partnership and high-touch service.